Ranbaxy Laboratories is trading lower by 4% at Rs 400 in morning trades on NSE, extending its previous day’s about 4% fall, after reporting a lower-than-expected numbers on the profit front for the quarter ended December 31, 2012 (Q4).
The pharmaceutical company has reported a consolidated net loss of Rs 492 crore in Q4 against analyst expectations of profits.
“Profitability for Q4’12 was primarily impacted by the voluntary recall which impacted the quarter by Rs 186 crore and mark to market (MTM) loss of Rs 262 crore on long term derivative contracts and foreign currency loans owing to a weaker rupee,” Ranbaxy said in a press release.
“The main disappointment came on the operating profit margin (OPM) front which came in at 3.4% vs our expectation of 9.3%, said analyst at Angel Broking.
On the sales front, the company reported a 28.8% decline to end the period at Rs 2,671 crore against analyst expectation of Rs 2,640 crore.
The stock opened at Rs 418 and has seen a combined 562,275 shares changing hands on the counter so far on NSE and BSE.
The pharmaceutical company has reported a consolidated net loss of Rs 492 crore in Q4 against analyst expectations of profits.
“Profitability for Q4’12 was primarily impacted by the voluntary recall which impacted the quarter by Rs 186 crore and mark to market (MTM) loss of Rs 262 crore on long term derivative contracts and foreign currency loans owing to a weaker rupee,” Ranbaxy said in a press release.
“The main disappointment came on the operating profit margin (OPM) front which came in at 3.4% vs our expectation of 9.3%, said analyst at Angel Broking.
On the sales front, the company reported a 28.8% decline to end the period at Rs 2,671 crore against analyst expectation of Rs 2,640 crore.
The stock opened at Rs 418 and has seen a combined 562,275 shares changing hands on the counter so far on NSE and BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%